The first cancer diagnostic product-ExoDX Lung (ALK) was launched by Exosome Diagnostics in 2016, which is an exosome-based technology detecting RNA and ctDNA simultaneously and performing real-time screening for EML4-ALK mutations in patients with non-small cell lung cancer (NSCLC). Here, EML4 is linked to non-small cell lung carcinoma.